膠質(zhì)瘤是原發(fā)性中樞神經(jīng)系統(tǒng)腫瘤最常見的組織學類型，其起源于星形細胞、少突膠質(zhì)細胞和室管膜來源的膠質(zhì)細胞，生長多呈廣泛浸潤性，是最具侵襲性的原發(fā)性腦腫瘤。世界衛(wèi)生組織（WHO）按腫瘤細胞的惡性程度將腦膠質(zhì)瘤分為Ⅰ～Ⅳ級，其中I級惡性程度最低、預后最好，IV級惡性程度最高、預后最差。膠質(zhì)瘤目前的標準治療方法包括手術切除和放化療，但這些手段并不能帶來滿意的治療效果，這與膠質(zhì)瘤在腦內(nèi)的侵襲性生長、血腦屏障限制和腫瘤耐藥相關。近年來，隨著腫瘤基因組和免疫微環(huán)境等研究的深入，膠質(zhì)瘤與宿主免疫系統(tǒng)間的關系逐漸被闡明，免疫治療等新技術逐步發(fā)展，為進一步改善膠質(zhì)瘤臨床預后帶來希望。從膠質(zhì)瘤與宿主免疫系統(tǒng)間的關系入手，對目前膠質(zhì)瘤免疫療法的可行性進行探討和綜述，為膠質(zhì)瘤的有效治療提供參考。

Glioma is the most common histological type of primary central nervous system tumors, which originates from astrocytes, oligodendrocytes and glial cells of ependymal origin, grows mostly widely infiltrative, and is an aggressive primary brain tumor. The World Health Organization (WHO) classifies gliomas into grades I to IV according to the malignancy of tumor cells, with grade I having the lowest malignancy and the best prognosis, and grade IV having the highest malignancy and the worst prognosis. The current standard treatment for gliomas, including surgical resection and chemoradiotherapy, does not result in satisfactory therapeutic outcomes, which are associated with aggressive growth of gliomas, blood-brain barrier restriction, and tumor resistance. In recent years, with the deepening of the study of tumor genome and immune microenvironment, the relationship between glioma and host immune system has been gradually elucidated, and new technologies such as immunotherapy have been gradually developed, which brings hope for further improving the clinical prognosis of glioma. This article discusses and reviews the feasibility of current glioma immunotherapy starting from the relationship between glioma and host immune system, providing a reference for the effective treatment of glioma.

R979.1

貴州省科技計劃項目(黔科合［2016］支撐 2905)